USA - NASDAQ:WGS - US81663L2007 - Common Stock
The current stock price of WGS is 136.44 USD. In the past month the price increased by 14.58%. In the past year, price increased by 104.46%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.72 | 101.80B | ||
| CI | THE CIGNA GROUP | 9.53 | 72.23B | ||
| LH | LABCORP HOLDINGS INC | 16.81 | 22.10B | ||
| DGX | QUEST DIAGNOSTICS INC | 19.14 | 20.89B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 112.65 | 20.35B | ||
| GH | GUARDANT HEALTH INC | N/A | 12.20B | ||
| HIMS | HIMS & HERS HEALTH INC | 72.26 | 8.82B | ||
| DVA | DAVITA INC | 13.39 | 8.84B | ||
| CHE | CHEMED CORP | 20.34 | 6.52B | ||
| RDNT | RADNET INC | 195.92 | 5.73B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 32.98 | 5.96B | ||
| OPCH | OPTION CARE HEALTH INC | 19.49 | 4.71B |
GeneDx Holdings Corp. operates as a health intelligence company. The company is headquartered in Stamford, Connecticut and currently employs 1,000 full-time employees. The company went IPO on 2020-09-04. The firm operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. The company operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. The company offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
GENEDX HOLDINGS CORP
333 Ludlow Street, North Tower, 6Th Floor
Stamford CONNECTICUT US
Employees: 1000
Phone: 18887291206
GeneDx Holdings Corp. operates as a health intelligence company. The company is headquartered in Stamford, Connecticut and currently employs 1,000 full-time employees. The company went IPO on 2020-09-04. The firm operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. The company operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. The company offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
The current stock price of WGS is 136.44 USD. The price decreased by -2.48% in the last trading session.
WGS does not pay a dividend.
WGS has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
The PE ratio for GENEDX HOLDINGS CORP (WGS) is 72.57. This is based on the reported non-GAAP earnings per share of 1.88 and the current share price of 136.44 USD.
GENEDX HOLDINGS CORP (WGS) has a market capitalization of 3.92B USD. This makes WGS a Mid Cap stock.
ChartMill assigns a technical rating of 10 / 10 to WGS. When comparing the yearly performance of all stocks, WGS is one of the better performing stocks in the market, outperforming 93.31% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to WGS. While WGS has a great health rating, there are worries on its profitability.
Over the last trailing twelve months WGS reported a non-GAAP Earnings per Share(EPS) of 1.88. The EPS increased by 274.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.52% | ||
| ROA | 0.42% | ||
| ROE | 0.71% | ||
| Debt/Equity | 0.18 |
13 analysts have analysed WGS and the average price target is 132.26 USD. This implies a price decrease of -3.06% is expected in the next year compared to the current price of 136.44.
For the next year, analysts expect an EPS growth of 644.01% and a revenue growth 45.41% for WGS